Efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a meta-analysis

被引:0
作者
Meng, Xiaoyan [1 ]
Gan, Jinghua [1 ]
Liu, Guangnan [1 ]
Qin, Enyuan [1 ]
Ning, Haibo [2 ]
机构
[1] Guangxi Med Univ, Dept Respirat, Affiliated Hosp 2, 166 East Univ Rd, Naning 530007, Guangxi, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 4, Dept Gen Surg, Naning, Guangxi, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2018年 / 11卷 / 03期
关键词
Mepolizumab; severe eosinophilic asthma; meta-analysis; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ANTI-INTERLEUKIN-5;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The efficacy and safety of mepolizumab in patients with eosinophilic asthma remains controversial. Our meta-analysis was undertaken to evaluate the efficacy and safety of mepolizumab in patients with eosinophilic asthma. Methods: PubMed, EMBASE, Cochrane Library, and Clinical Trials.gov databases were searched for randomized controlled trials (RCTs). The incidence of exacerbation was the efficacy endpoint. The safety endpoint was the incidence of adverse events. Results: Eight RCTs and 1818 patients were included in our meta-analysis. Mepolizumab associated with lower risk compared with placebo in the endpoint of exacerbation when a dose of 750 mg was used (Risk Ratio (RR) 0.77 95% confidence intervals (CIs) 0.60 to 0.98; P=0.03; I-2=48%) and similar results were obtained with a dose of 100 mg (RR 0.58 95% CI 0.44 to 0.78; P=0.0003; I-2=0). The risk of adverse events was decreased compared with placebo at the dose of 50 mg (RR 0.72 95% CI 0.53 to 0.99; P=0.05; I-2=0). In the subgroup analysis of a 250 mg dose (standard mean differences (SMD) 2.00; 95% CI 1.72 to 2.27; P<0.00001) and a 100 mg dose (SMD 3.71; 95% CI 1.28 to 6.14; P=0.003; I-2=99%), mepolizumab significantly increased the value of FEV1 more than placebo. Meanwhile mepolizumab associated with greater decrease in blood eosinophil counts but did not confer a significant difference in the change of sputum eosinophil counts and Asthma Control Questionnaire (ACQ). Conclusion: Mepolizumab associated with a significant reduction in endpoint of exacerbation and adverse events, but an increased value of FEV1. Meanwhile, mepolizumab-treated patients experienced significant decreases in blood eosinophil levels and ACQ compared with those who received placebo.
引用
收藏
页码:1483 / +
页数:10
相关论文
共 18 条
  • [1] Barnes NC, 2004, AM J RESP CRIT CARE, V170, P830, DOI 10.1164/rccm.2408006
  • [2] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
    Bel, Elisabeth H.
    Wenzel, Sally E.
    Thompson, Philip J.
    Prazma, Charlene M.
    Keene, Oliver N.
    Yancey, Steven W.
    Ortega, Hector G.
    Pavord, Ian D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) : 1189 - 1197
  • [3] Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions
    Büttner, C
    Lun, A
    Splettstoesser, T
    Kunkel, G
    Renz, H
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (05) : 799 - 803
  • [4] International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
    Chung, Kian Fan
    Wenzel, Sally E.
    Brozek, Jan L.
    Bush, Andrew
    Castro, Mario
    Sterk, Peter J.
    Adcock, Ian M.
    Bateman, Eric D.
    Bel, Elisabeth H.
    Bleecker, Eugene R.
    Boulet, Louis-Philippe
    Brightling, Christopher
    Chanez, Pascal
    Dahlen, Sven-Erik
    Djukanovic, Ratko
    Frey, Urs
    Gaga, Mina
    Gibson, Peter
    Hamid, Qutayba
    Jajour, Nizar N.
    Mauad, Thais
    Sorkness, Ronald L.
    Teague, W. Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) : 343 - 373
  • [5] FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]
  • [6] A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
    Flood-Page, Patrick
    Swenson, Cheri
    Faiferman, Isidore
    Matthews, John
    Williams, Michael
    Brannick, Lesley
    Robinson, Douglas
    Wenzel, Sally
    Busse, William
    Hansel, Trevor T.
    Barnes, Neil C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (11) : 1062 - 1071
  • [7] Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway
    Flood-Page, PT
    Menzies-Gow, AN
    Kay, AB
    Robinson, DS
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (02) : 199 - 204
  • [8] Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
    Haldar, Pranabashis
    Brightling, Christopher E.
    Singapuri, Amisha
    Hargadon, Beverley
    Gupta, Sumit
    Monteiro, William
    Bradding, Peter
    Green, Ruth H.
    Wardlaw, Andrew J.
    Ortega, Hector
    Pavord, Ian D.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (03) : 921 - +
  • [9] Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
    Leckie, MJ
    ten Brinke, A
    Khan, J
    Diamant, Z
    O'Connor, BJ
    Walls, CM
    Mathur, AK
    Cowley, HC
    Chung, KF
    Djukanovic, R
    Hansel, TT
    Holgate, T
    Sterk, PJ
    Barnes, PJ
    [J]. LANCET, 2000, 356 (9248) : 2144 - 2148
  • [10] Microfluidics for Synthesis of Peptide-Based PET Tracers
    Liu, Yang
    Tian, Mei
    Zhang, Hong
    [J]. BIOMED RESEARCH INTERNATIONAL, 2013, 2013